Pfizer Inc. and Merck KGAAreported a Phase III failure for their PD-L1 inhibitor Bavencio (avelumab) in second-line non-small cell lung cancer on Feb. 15, which at least one analyst sees as portending a poor outcome for an ongoing Phase III study in the first-line setting for this tumor type.
The checkpoint inhibitor failed, in the 792-patient JAVELIN Lung 200 study, to meet its primary endpoint of improving overall survival...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)